• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

流行前和 COVID-19 恢复期个体中的交叉反应性和单反应性 SARS-CoV-2 CD4+ T 细胞。

Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals.

机构信息

Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.

Virginia Mason Franciscan Health, Seattle, Washington, United States of America.

出版信息

PLoS Pathog. 2021 Dec 29;17(12):e1010203. doi: 10.1371/journal.ppat.1010203. eCollection 2021 Dec.

DOI:10.1371/journal.ppat.1010203
PMID:34965282
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8769337/
Abstract

Class II tetramer reagents for eleven common DR alleles and a DP allele prevalent in the world population were used to identify SARS-CoV-2 CD4+ T cell epitopes. A total of 112, 28 and 42 epitopes specific for Spike, Membrane and Nucleocapsid, respectively, with defined HLA-restriction were identified. Direct ex vivo staining of PBMC with tetramer reagents was used to define immunodominant and subdominant T cell epitopes and estimate the frequencies of these T cells in SARS-CoV-2 exposed and naïve individuals. Majority of SARS-CoV-2 epitopes identified have <67% amino acid sequence identity with endemic coronaviruses and are unlikely to elicit high avidity cross-reactive T cell responses. Four SARS-CoV-2 Spike reactive epitopes, including a DPB104:01 restricted epitope, with ≥67% amino acid sequence identity to endemic coronavirus were identified. SARS-CoV-2 T cell lines for three of these epitopes elicited cross-reactive T cell responses to endemic cold viruses. An endemic coronavirus Spike T cell line showed cross-reactivity to the fourth SARS-CoV-2 epitope. Three of the Spike cross-reactive epitopes were subdominant epitopes, while the DPB104:01 restricted epitope was a dominant epitope. Frequency analyses showed Spike cross-reactive T cells as detected by tetramers were present at relatively low frequency in unexposed people and only contributed a small proportion of the overall Spike-specific CD4+ T cells in COVID-19 convalescent individuals. In total, these results suggested a very limited number of SARS-CoV-2 T cells as detected by tetramers are capable of recognizing ccCoV with relative high avidity and vice versa. The potentially supportive role of these high avidity cross-reactive T cells in protective immunity against SARS-CoV-2 needs further studies.

摘要

使用针对世界人群中常见的 11 种 DR 等位基因和一种 DP 等位基因的 II 类四聚体试剂来鉴定 SARS-CoV-2 CD4+ T 细胞表位。分别鉴定出针对 Spike、Membrane 和 Nucleocapsid 的 112、28 和 42 个具有明确 HLA 限制的特异性表位。使用四聚体试剂直接对 PBMC 进行体外染色,以鉴定免疫优势和亚优势 T 细胞表位,并估计这些 T 细胞在 SARS-CoV-2 暴露和未暴露个体中的频率。鉴定出的大多数 SARS-CoV-2 表位与地方性冠状病毒的氨基酸序列同一性<67%,不太可能引起高亲和力的交叉反应性 T 细胞反应。鉴定出 4 个 SARS-CoV-2 Spike 反应性表位,包括一个与地方性冠状病毒具有≥67%氨基酸序列同一性的 DPB104:01 限制性表位。这三个表位中的三个 SARS-CoV-2 表位为亚优势表位,而 DPB104:01 限制性表位为优势表位。频率分析表明,通过四聚体检测到的 Spike 交叉反应性 T 细胞在未暴露人群中的频率相对较低,仅在 COVID-19 恢复期个体的总 Spike 特异性 CD4+ T 细胞中占很小比例。总的来说,这些结果表明,通过四聚体检测到的 SARS-CoV-2 T 细胞数量非常有限,能够以相对高的亲和力识别 ccCoV,反之亦然。这些高亲和力交叉反应性 T 细胞在 SARS-CoV-2 保护性免疫中的潜在支持作用需要进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/cae20e13124c/ppat.1010203.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/72132c964f41/ppat.1010203.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/a95382ba3315/ppat.1010203.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/0ece14cccc67/ppat.1010203.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/4e19ccf6d9e0/ppat.1010203.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/69f4430d8dac/ppat.1010203.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/870cccca7655/ppat.1010203.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/cae20e13124c/ppat.1010203.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/72132c964f41/ppat.1010203.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/a95382ba3315/ppat.1010203.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/0ece14cccc67/ppat.1010203.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/4e19ccf6d9e0/ppat.1010203.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/69f4430d8dac/ppat.1010203.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/870cccca7655/ppat.1010203.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ff/8769337/cae20e13124c/ppat.1010203.g007.jpg

相似文献

1
Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals.流行前和 COVID-19 恢复期个体中的交叉反应性和单反应性 SARS-CoV-2 CD4+ T 细胞。
PLoS Pathog. 2021 Dec 29;17(12):e1010203. doi: 10.1371/journal.ppat.1010203. eCollection 2021 Dec.
2
CD8 T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity.针对 SARS-CoV-2 核衣壳表位具有特异性的 CD8 T 细胞表现出高的初始前体频率和 TCR 多样性。
Immunity. 2021 May 11;54(5):1066-1082.e5. doi: 10.1016/j.immuni.2021.04.009. Epub 2021 Apr 15.
3
Limited Recognition of Highly Conserved Regions of SARS-CoV-2.有限识别 SARS-CoV-2 的高度保守区域。
Microbiol Spectr. 2022 Feb 23;10(1):e0278021. doi: 10.1128/spectrum.02780-21.
4
SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses.SARS-CoV-2-血清阴性个体针对 SARS-CoV-2 核蛋白中的 CTL 表位,这些表位与普通感冒冠状病毒发生交叉反应。
Front Immunol. 2021 Apr 28;12:627568. doi: 10.3389/fimmu.2021.627568. eCollection 2021.
5
SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects.在 COVID-19 康复者中鉴定出的 SARS-CoV-2 特异性记忆 T 细胞表位。
Virus Res. 2021 Oct 15;304:198508. doi: 10.1016/j.virusres.2021.198508. Epub 2021 Jul 27.
6
Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines.常见人类病原体和疫苗对 SARS-CoV-2 的潜在交叉反应性免疫。
Front Immunol. 2020 Oct 16;11:586984. doi: 10.3389/fimmu.2020.586984. eCollection 2020.
7
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.SARS-CoV-2 反应性 T 细胞在健康供体和 COVID-19 患者中的研究。
Nature. 2020 Nov;587(7833):270-274. doi: 10.1038/s41586-020-2598-9. Epub 2020 Jul 29.
8
Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2.对 SARS-CoV-2 的 CD4 T 细胞反应的免疫优势和交叉反应性进行克隆分析。
Science. 2021 Jun 18;372(6548):1336-1341. doi: 10.1126/science.abg8985. Epub 2021 May 18.
9
Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity.鉴定 SARS-CoV-2 核衣壳和刺突 T 细胞表位以评估 T 细胞免疫。
J Virol. 2021 Feb 24;95(6). doi: 10.1128/JVI.02002-20.
10
Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naïve CD8 T cells of unexposed individuals.SARS-CoV-2 的免疫原性 T 细胞表位可被未暴露个体的循环记忆和幼稚 CD8 T 细胞识别。
EBioMedicine. 2021 Oct;72:103610. doi: 10.1016/j.ebiom.2021.103610. Epub 2021 Oct 6.

引用本文的文献

1
Aging and Viral Evolution Impair Immunity Against Dominant Pan-Coronavirus-Reactive T Cell Epitope.衰老和病毒进化削弱针对主要泛冠状病毒反应性T细胞表位的免疫力。
Eur J Immunol. 2025 Jul;55(7):e51888. doi: 10.1002/eji.202551888.
2
A tentative exploration for the association between influenza virus infection and SARS-CoV-2 infection in Shihezi, China: A test-negative study.中国石河子流感病毒感染与新型冠状病毒感染关联的初步探索:一项检测阴性研究
Infect Dis Model. 2024 Oct 9;10(1):201-206. doi: 10.1016/j.idm.2024.10.002. eCollection 2025 Mar.
3
Humanized Major Histocompatibility Complex Transgenic Mouse Model Can Play a Potent Role in SARS-CoV-2 Human Leukocyte Antigen-Restricted T Cell Epitope Screening.

本文引用的文献

1
Impact of SARS-CoV-2 variants on the total CD4 and CD8 T cell reactivity in infected or vaccinated individuals.新冠病毒变异株对感染或接种个体中总 CD4 和 CD8 T 细胞反应性的影响。
Cell Rep Med. 2021 Jul 20;2(7):100355. doi: 10.1016/j.xcrm.2021.100355. Epub 2021 Jul 2.
2
Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2.对 SARS-CoV-2 的 CD4 T 细胞反应的免疫优势和交叉反应性进行克隆分析。
Science. 2021 Jun 18;372(6548):1336-1341. doi: 10.1126/science.abg8985. Epub 2021 May 18.
3
CD8 T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity.
人源化主要组织相容性复合体转基因小鼠模型在严重急性呼吸综合征冠状病毒2人白细胞抗原限制性T细胞表位筛选中可发挥重要作用。
Vaccines (Basel). 2025 Apr 15;13(4):416. doi: 10.3390/vaccines13040416.
4
Lack of memory recall in human CD4 T cells elicited by the first encounter with SARS-CoV-2.人类CD4 T细胞首次接触严重急性呼吸综合征冠状病毒2(SARS-CoV-2)后引发的记忆回忆缺失。
iScience. 2024 May 17;27(6):109992. doi: 10.1016/j.isci.2024.109992. eCollection 2024 Jun 21.
5
High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4 and CD8 memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients.高频率的α型普通感冒冠状病毒/SARS-CoV-2 交叉反应性功能性 CD4 和 CD8 记忆 T 细胞与未接种疫苗的 COVID-19 患者免受有症状和致命 SARS-CoV-2 感染有关。
Front Immunol. 2024 Mar 28;15:1343716. doi: 10.3389/fimmu.2024.1343716. eCollection 2024.
6
The Influence of Cross-Reactive T Cells in COVID-19.交叉反应性T细胞在COVID-19中的影响。
Biomedicines. 2024 Mar 2;12(3):564. doi: 10.3390/biomedicines12030564.
7
Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8 T cells in persons with previous COVID-19.重复 mRNA 疫苗接种可依次增强既往感染过 COVID-19 人群的 SARS-CoV-2 特异性 CD8 T 细胞。
Nat Immunol. 2024 Jan;25(1):166-177. doi: 10.1038/s41590-023-01692-x. Epub 2023 Dec 6.
8
Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.鉴定人冠状病毒 OC43 感染细胞的免疫肽组谱,确定了季节性冠状病毒特异性的 CD4 T 细胞表位或与 SARS-CoV-2 交叉反应的表位。
PLoS Pathog. 2023 Jul 27;19(7):e1011032. doi: 10.1371/journal.ppat.1011032. eCollection 2023 Jul.
9
Targets and cross-reactivity of human T cell recognition of common cold coronaviruses.人类 T 细胞识别普通感冒冠状病毒的靶点和交叉反应性。
Cell Rep Med. 2023 Jun 20;4(6):101088. doi: 10.1016/j.xcrm.2023.101088. Epub 2023 May 29.
10
Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4 T-cell response with pre-primed responses directed against common cold coronaviruses.针对 SARS-CoV-2 NSP12 定向 CD4 T 细胞反应与针对普通感冒冠状病毒的预先存在反应的广泛交叉反应性的证据。
Front Immunol. 2023 May 5;14:1182504. doi: 10.3389/fimmu.2023.1182504. eCollection 2023.
针对 SARS-CoV-2 核衣壳表位具有特异性的 CD8 T 细胞表现出高的初始前体频率和 TCR 多样性。
Immunity. 2021 May 11;54(5):1066-1082.e5. doi: 10.1016/j.immuni.2021.04.009. Epub 2021 Apr 15.
4
CD8 T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses.针对 SARS-CoV-2 核衣壳表位的免疫优势 CD8 T 细胞与选择性季节性冠状病毒发生交叉反应。
Immunity. 2021 May 11;54(5):1055-1065.e5. doi: 10.1016/j.immuni.2021.04.006. Epub 2021 Apr 13.
5
SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8 T cell activation in COVID-19 patients.SARS-CoV-2 全基因组 T 细胞表位图谱分析揭示了 COVID-19 患者中的免疫优势和大量 CD8+T 细胞激活。
Sci Immunol. 2021 Apr 14;6(58). doi: 10.1126/sciimmunol.abf7550.
6
Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses.CD4+ T 细胞受体交叉识别 SARS-CoV-2 和地方性冠状病毒的功能特征。
J Clin Invest. 2021 May 17;131(10). doi: 10.1172/JCI146922.
7
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses.T 细胞检测可区分临床和亚临床 SARS-CoV-2 感染与交叉反应性抗病毒反应。
Nat Commun. 2021 Apr 6;12(1):2055. doi: 10.1038/s41467-021-21856-3.
8
SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63.SARS-CoV-2 mRNA 疫苗可诱导广泛的 CD4+ T 细胞反应,这些反应可识别 SARS-CoV-2 变体和 HCoV-NL63。
J Clin Invest. 2021 May 17;131(10). doi: 10.1172/JCI149335.
9
Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection.原发感染 6 个月后仍能保持对 SARS-CoV-2 的特异性 T 细胞免疫。
Nat Immunol. 2021 May;22(5):620-626. doi: 10.1038/s41590-021-00902-8. Epub 2021 Mar 5.
10
In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19.基于计算机的 SARS-CoV-2 特异性 B 细胞表位预测及 ELISA 验证在 COVID-19 血清学诊断中的应用。
Sci Rep. 2021 Feb 22;11(1):4290. doi: 10.1038/s41598-021-83730-y.